Dapagliflozin Cuts CV Risk in Heart Failure With Preserved LVEF
MONDAY, Aug. 29, 2022 -- For patients with heart failure with mildly reduced or preserved ejection fraction, the sodium glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the combined risk for worsening heart failure or cardiovascular...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Dapagliflozin | Forxiga | Heart | Heart Failure | Pharmaceuticals | SGLT2 Inhibitors | Sodium